Immuron Limited · ASX:IMC
Immuron — Shareholder Meeting (October 2020)
11 slides from Immuron's shareholder meeting presentation, Oct 29, 2020
Slide 1: Forging Commercial & Clinical Pathways Targeting Infectious Diseases with Oral Immunotherapies
FORGING COMMERCIAL & CLINICAL PATHWAYS TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES – OCTOBER, 2020 JERRY KANELLOS, Ph.D. CEO NASDAQ: IMRN ASX: IMC 1
Slide 2: Development Pipeline
DEVELOPMENT PIPELINE Commercial Products IMM-124E. IMM-529 4 Naval Medical Research Center PRE-CLINICAL PHASE | PHASE II PHASE III MARKET Travelan® - commercial product Australia Protectyn® - commercial product Australia Travelan® - commercial product Canada Travelan® - commercial product USA i) Tra
Slide 3: Travelan Commercial Profile: Global Immuron Sales (Gross) AUD
TRAVELAN® COMMERCIAL PROFILE: A UD $ - 3 $500,000 $1,000,000 $1,500,000 $2,000,000 $2,500,000 $3,000,000 FY17A FY18A FY19A FY20A $1.38M $2.01M $2.6M $2.7M Global Immuron Sales (Gross) - AUD
Slide 4: IMM-124E Drug Development Plan: Register Travelan as a Drug in the USA with the FDA
Plan to register Travelan® as a drug in the USA with the FDA to reduce the risk of Travelers’ Diarrhea (TD) in travelers to endemic areas: IMM - 124E DRUG DEVELOPMENT PLAN Execute Prevention Trial and File Registration Package 4 File IND with Plan for Double - Blind, Placebo Controlled Trial for Pre
Slide 5: US Sales Forecast for Travelan: If Approved as Drug
US SALES FORECAST FOR TRAVELAN®: IF APPROVED AS DRUG Market potential figure derived from: 2014 figures of US citizens traveling to high risk destinations for TD (44.3 million) 1 and obtaining pretravel advice (22.2 million) 2 . Sources of pre - travel advice include primary care provider, travel me
Slide 6: Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Non-Antibiotic OTC Products in TD Prevention (P4TD)
A RANDOMIZED, DOUBLE - BLIND, PLACEBO - CONTROLLED TRIAL EVALUATING THE EFFICACY OF NON - ANTIBIOTIC OTC PRODUCTS IN TRAVELERS’ DIARRHEA (TD) PREVENTION (P4TD) 6 CURRENT STATUS – PLAN TO C 0 MMENCE ENROLMENT JUNE 2021 Primary Objective : To evaluate the clinical efficacy of Travelan®, Florastor® and
Slide 7: Two Human Clinical Trials Planned: New Drug to Reduce Risk of Infectious Diarrhea
Two Human Clinical Trials Planned: New Drug to Reduce the risk of Infectious Diarrhea Caused by Campylobacter and by ETEC US NAVEL MEDICAL RESEARCH CENTRE DRUG DEVELOPMENT PLAN Execute Prevention Trials 7 File IND with Plans for two Double - Blind, Placebo Controlled Prevention Trials Hold Pre - IND
Slide 8: IMM-529 Drug Development Plan: Prevent Recurrent Clostridioides difficile Infection
Develop clinical protocol for FDA approval as drug to prevent recurrent Clostridiodes difficile Infection: IMM - 529 DRUG DEVELOPMENT PLAN Execute recurrence prevention trial 8 File IND with plan for placebo controlled trial for prevention of disease recurrence Hold pre - IND meeting to discuss clin
Slide 9: Immuron Reports Neutralizing Activity Against SARS-CoV-2
Immuron Reports Neutralizing activity Against SARS - CoV - 2 9 Key Points Immuron’s Hyper - immune Bovine Colostrum used to manufacture Travelan® and Protectyn® demonstrates antiviral activity against the COVID - 19 virus in laboratory studies Immuron’s technology platform offers a potential new ora
Slide 10: IMM-124E SARS-CoV-2 Research & Development Proposal: Current Status Research
IMM - 124E SARS - COV - 2 RESEARCH & DEVELOPMENT PROPOSAL 10 CURRENT STATUS RESEARCH & DEVELOPMENT Reached out to local, national, and international potential research collaborators to advance this work and assist in the further characterization of the neutralization activity of SARS - CoV - 2 obser
Slide 11: IMM-124E SARS-CoV-2 Research & Development Proposal: Current Status Clinical
IMM - 124E SARS - COV - 2 RESEARCH & DEVELOPMENT PROPOSAL 11 CURRENT STATUS CLINICAL PROPOSALS • Consultancy agreement executed with Professor Teena Chopra, Professor of Medicine Wayne State University School of Medicine, Detroit » Professor Chopra is building a registry of the patients presenting w